PHOENIX, September 9, 2013 – Avella Specialty Pharmacy is voluntarily recalling two compounded sterile medications. The recall is a result of concerns of sterility assurance with the specialty pharmacy’s independent testing laboratory, Front Range Laboratories. Avella is recalling the following medications: 


Lot Number


Bevacizumab 1.25 mg/0.05 mL PF



Vancomycin PF (BSS) 1%




Avella was notified that in a recent inspection of Front Range Labs, FDA investigators observed methods used to assess sterility and other qualities (e.g. strength and stability) which may have resulted in Avella receiving inaccurate laboratory test results on the specified lots. FDA has raised concerns that test results obtained from Front Range Labs may not be reliable. Therefore, Avella decided to conduct this voluntary recall out of an abundance of caution.  Avella has discontinued its relationship with Front Range Labs as a result of this issue.

If microbial contamination occurs in medications intended to be sterile, patients are at risk of serious infections that may be life threatening. To date, Avella has not received any reports of adverse events related to the recall.  The recalled products were dispensed directly to healthcare providers nationwide. The medications can be identified based on product label and corresponding medication name and lot number.

Avella Specialty Pharmacy is notifying customers of the voluntary recall by phone and mail.  Customers that have any of the medications that are being recalled should immediately discontinue use and return the unused portion to Avella.

Patients and healthcare providers with questions regarding this recall can contact Avella at (877) 738-0797 Monday through Friday between 6am and 6pm Pacific Standard Time or via e-mail at Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.